Together

NATIONAL KIDNEY FOUNDATION
ANNUAL REPORT FY21
TABLE OF CONTENTS

A Message from 4
Advancing Kidney Transplantation 10
Focus on Patients 12
Kidney Health Awareness for All 14
COVID-19 at a Glance 18
Making Lives Better Research 20
Changing Laws and Influencing Minds 22
Aiding the Professionals 26
Corporate Champion 28
NKF Serving the Local Community 30
Our Financial Overview 34
What’s to Come in FY22 46

Fueled by passion and urgency, the National Kidney Foundation (NKF) is a lifeline for all people affected by kidney disease, also known as chronic kidney disease (CKD). As pioneers of scientific research and innovation, NKF focuses on the whole patient through the lens of kidney health. Relentless in our work, we enhance lives through action, education, and accelerating change. The pages within highlight NKF’s efforts between April 1, 2020 to March 31, 2021, our fiscal year 2021.
A MESSAGE FROM leadership

For more than seven decades, NKF has worked together with patients, advocates, clinicians, researchers, lawmakers, the private sector, and financial contributors to improve the lives of patients through advocacy, education, and by accelerating change.

We proved in fiscal year 2021, that not even a pandemic could stop our efforts and that this past year gave us a new meaning of the word “together.”

COVID-19 forced us to move all our on-going work to virtual and remote operations and to generate new efforts for a novel disease that damages kidneys and created a new subset of kidney patients. Despite the challenges, together, we achieved one of our most groundbreaking years in our history.

When the shutdown started, we immediately began advocating for patients who needed dialysis, transplants, and for people with COVID-19 damaged kidneys. We fought for early and free COVID-19 screening, personal protective equipment, and vaccines for kidney patients and dialysis center workers. We urged the federal government to clarify that organ transplants and dialysis-related procedures were “essential surgeries.”

When reports came in that kidney patients could be denied medical services during the height of COVID-19 hospitalizations because of their status as end-stage kidney disease patients, we immediately turned our powerful megaphone toward hospitals, politicians, and policy agencies to call for an end to such discrimination toward our patients. Earlier than most, we sounded the alarm when we learned that COVID-19 was hitting communities of color especially hard and demanded more public resources immediately to level care.

In December, we reached one of our most important goals when the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act was signed into law. It will change the lives of thousands of patients receiving Medicare, who can now afford transplantation because their immunosuppressive drugs will be covered for the life of their transplant.

Today, only a fraction of patients with kidney failure will ever get a transplant. To make the problem even more intolerable, people of color are disproportionately less likely to have access to transplantation, thus creating yet another system plagued by inequality. We believe our new initiative Transplants for All will ensure that any patient who wants a transplant can get one.

In February, we launched the national NKF Patient Network. It is the only kidney disease registry that has both patient-entered data combined with electronic health records. Patients with all stages of kidney disease can register and add their important health information. This powerful research tool will improve the lives of people with kidney disease by better informing research, clinical care, drug development, and health policy decisions, as well as give kidney patients the tools they need to stay educated and healthy. Please take some time to learn more about it within this report.

During this difficult year, we all know that our society faced more than just a historic pandemic, it faced injustices, unrest, and political division. It prompted us to take a bold stand in addressing the healthcare disparities that plague our communities of color and delay the diagnosis and treatment of kidney disease. We launched a joint Task Force with the American Society of Nephrology to examine the role of race in diagnosing and treating kidney disease. We also launched our first-ever Health Equity Advisory Committee, responsible for directing and championing NKF’s health equity, community health, and social justice efforts through research, education, and key partnerships.

As you read through these pages of our FY21 Annual Report, please think about the many contributors who joined us to support kidney patients. It is because of their faith in us and continued giving that we accomplished so much this year.

Thank you for all that you have contributed to this important work.

A message to you from NKF Chair and transplant recipient Anthony Tuggle
KIDNEY DISEASE
at a Glance

1 IN 3 adults in the U.S. are at risk of kidney disease.

37 MILLION adults in the U.S. have kidney disease.

HISPANIC OR LATINO adults are 1.3 times more likely to develop kidney failure than non-Hispanics.

BLACK OR AFRICAN AMERICANS suffer from kidney failure about 3 times more than White Americans.

35% of all patients treated for kidney failure are Black or African American yet they represent only 13% of the U.S. population.

Our Leadership

Introducing the NKF Board

Year after year, each class of the NKF Board of Directors has served with a personal connection to kidney disease.

Manish Agarwal, President and COO, Attain LLC, McLean, VA
Personal connection: Mr. Agarwal is a transplant recipient and is passionate about kidney health. He actively serves NKF by serving the National Capital Area as Chair of the Board.

Anne Barth, Chief Information Officer, Brown & Toland Physicians, Bay Area, CA
Personal connection: Ms. Barth’s engagement with NKF began as part of her passion for kidney transplantation and when a close friend became a kidney donor.

Matthew Cooper, MD, Director, Kidney and Pancreas Transplantation, MedStar Georgetown Transplant Institute, Professor of Surgery, Georgetown University School of Medicine, Washington, DC
Personal connection: Dr. Cooper’s work with NKF is centered on improving the lives of people with kidney disease and supporting the need for organ transplantation for those with kidney failure.

Joseph Cosgrove, Chairman, President and CEO, Pentec Health, Inc., Bloomsburg, PA
Personal connection: Mr. Cosgrove’s mother-in-law and his best friend have kidney disease.

Jennifer Dasilva, President, Berlin Cameron, New York, NY
Personal connection: Ms. Dasilva knows that awareness is just part of the battle against the progression of kidney disease, so she is driven in her efforts to help spread NKF’s messages.

John Gerzema, Past NKF Chair, CEO, Harris Insights & Analytics, New York, NY
Personal connection: Mr. Gerzema experienced kidney damage as a child.

Orlando Hampton, Chef Customer Officer, Attini, Inc., Washington, DC
Personal connection: Mr. Hampton’s personal connection to kidney disease began when his stepfather’s kidneys failed due to a deteriorating condition that led to dialysis.

Tom Hough, Financial Consultant and Board Member, Bain Capital Specialty Finance, Plano, TX
Personal connection: His daughter received her first diagnosis of kidney stones at age 9. He joined the local NKF board to learn more about kidney disease and to help others deal with kidney disease.

Holly Kramer, MD, MPH, Past NKF President, Professor of Public Health Sciences and Medicine, Loyola University Medical Center, Maywood, IL
Personal connection: She is a second-generation kidney healthcare professional, dedicating her life to improving outcomes for people with this disease.

Kevin Longino, CEO, National Kidney Foundation, New York, NY
Personal connection: He is a kidney transplant recipient, and son and grandson of kidney patients.

Samuel J. Marchio, NKF Secretary, Regional Vice President, Federal Government Relations, Head of Congressional Affairs, Anthem, Inc., Washington, DC
Personal connection: He is passionate about kidney health, public health, and fundraising.

Tracy McKibben, Founder and CEO, MAC Energy Advisors, LLC, New York, NY
Personal connection: Ms. McKibben donated a kidney to her mother, who was on dialysis for several years.

Paul M. Palevsky, MD, NKF President, Professor of Medicine, University of Pittsburgh School of Medicine, Chief Renal Section, VA Pittsburgh Healthcare System, Pittsburgh
Personal connection: Dr. Palevsky has devoted his career to kidney health and is an international expert in acute kidney injury and critical care nephrology.

Art Pasquarella, CRE, EVP and COO, Equus Capital Partners, Ltd., Philadelphia
Personal connection: He is a living donor, and two of his immediate family members have received kidney transplants.

Stephen Pastan, MD, Associate Professor of Medicine, Division of Transplantation and Medical Director, Kidney and Pancreas Transplant Program, Emory University School of Medicine, Atlanta
Personal connection: He chose nephrology as a career due to the long-term personal relationships nephrologists form with their patients.

Sylvia Rosas, MD, MSCE, NKF President-Elect, Nephrologist, Epidemiologist, Joslin Diabetes Center, Inc., Boston
Personal connection: After receiving his diagnosis of glomerulonephritis, Mr. Stevenson received a kidney from his brother, Jim, in 1996, and has been a champion of trying to raise awareness about CKD and ultimately trying to find a cure.

Stephanie Stewart, MSW, LCSW, MBA, Operations Administrator, Mayo Clinic Health System, Mankato, MN
Personal connection: Ms. Stewart cares about improving the lives of people with CKD. Many of the individuals, mostly patients, with whom she has worked with have touched her life in very personal ways.

Sumeska Thavarajah, MD, Medical Director, Fresenius Kidney Care Merit Boulevard, Assistant Professor of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
Personal connection: She has been committed to education and dedicated to bringing community awareness about kidney disease through her work with the National Kidney Foundation serving Maryland and Delaware.

Anthony Tuggle, NKF Board Chair, President of Customer Operations, Afiniti, Inc., Washington, D.C.
Personal connection: A 22-year kidney transplant recipient, Mr. Tuggle is committed to working with NKF towards kidney disease prevention efforts.

Bradley A. Warady, MD, Division Director Pediatric Nephrology, Director Dialysis and Transplantation Children’s Mercy Hospital, Kansas City, MO
Personal connection: Dr. Warady has taken advantage of his opportunity as an NKF Board member to do what he has done throughout his career: advocate for children affected by kidney disease.
OUR LEADERSHIP

NATIONAL STAFF

Kevin Longino
Chief Executive Officer

Petros A. Gregoriou, CPA
Chief Financial Officer

Christopher Jackson
Chief People Officer

Dolores Machuca-Ruiz
Chief Marketing Officer

Joseph Vassalotti, MD
Chief Medical Officer

Kerry K. Willis, PhD
Chief Scientific Officer

Anthony S. Gucciardo
Senior Vice President
Strategic Partnerships

Jessica Joseph, MBA
Senior Vice President
Scientific Operations

Sharon Pearce
Senior Vice President,
Government Relations

Maureen Stone
Senior Vice President,
Development

Denise Andersen
Regional Vice President,
Northeast

Brenita Brooks
Regional Vice President,
Midwest, Central, Southwest

Susan Ketron, CFRE
Regional Vice President,
Resource Development

Donor and Resource Development,
Mid-Atlantic, Southeast, West

Jennifer Ching
Vice President of
Human Resources

Stephanie Cogan
Vice President,
Corporate Relations

Kelli Collins, MSW
Vice President,
Patient Engagement

James Echikson
Vice President,
Corporate Development

Andrew Gordon, CPA
Vice President,
Finance and Controller

Julie Kimbrough
Vice President,
Marketing, Communications,
and Public Affairs

Jacob Lane
Vice President,
Information Technology

Katarina E. Madej
Vice President,
Digital Marketing

Jennifer Martin
Vice President,
Program Development

Elizabeth Talbot-Montgomery
Vice President,
Learning Strategies and Primary
Care Programs

“Confronting disparities based on race and ethnicity in healthcare is critical for the National Kidney Foundation. And we believe we do our part by ensuring diversity and broad representation in NKF’s workforce. We know this has a profound impact now, and in the future, for our patients.”

— Christopher Jackson, NKF Chief People Officer
E IMAGINE A WORLD where no one ever dies while waiting for a kidney transplant.

We have three goals to make that dream a reality:

1. Increase living-donor transplantation;
2. Increase deceased-donor transplantation;
3. Increase eligibility and access to transplantation.

• We know that improvements are desperately needed to give equal access to transplantation to all patients, regardless of race, ethnicity, or income. So, we proudly announced the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDIGO) release of a commentary on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. This incredible work of kidney care stakeholders proposes numerous improvements to the KDIGO’s guidelines that will broaden access to the waitlist and improve equity in transplantation.

• NKF’s commitment to increasing transplantation for all is steadfast. In FY21, our team expanded and added new resources under THE BIO ASK: THE BIG GIVE (BABG) platform, including virtual components. First Steps to Transplant and Finding a Living Donor are interactive educational programs in webinar format that introduce the idea of transplantation to patients and how to share the need for a kidney. We also tested a virtual, “at home” version of our original BABG for patients on the waitlist. This will make it easier for patients without access to the in-person program around the country.

• In FY21, we saw the results of our patients’ and staffs’ advocacy efforts when five states, Kentucky, Missouri, New Jersey, Utah, and Washington, passed state legislation that protects living donors against insurance discrimination. Our advocates and staff also successfully advocated for paid leave for organ donation for state employees in Kentucky and city employees in Louisville, KY, and created a kidney disease task force in Illinois. We remain committed to advancing important legislation in every state that will make it easier for all living donors to give the gift of life and improve the quality of life of kidney patients.

• In December, we saw one of NKF’s most important goals reached when the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act was signed into law. NKF has been fighting for years for this federal legislation that will help tens of thousands of transplant patients and enable transplants as an option for many more. Many patients using Medicare could not even consider transplantation in the past because paying for immunosuppressive medication after the 36-month expiration date of coverage made the cost too expensive. Those patients may now be able to move towards transplant thanks to this new law. Providing equal access to a kidney transplant for patients with kidney failure is one of our top priorities and this legislation gets us closer to that end.

• In March, NKF partnered with a bipartisan coalition of members of the U.S. Congress to reintroduce The Living Donor Protection Act to protect living-donors from insurance and employment discrimination. The Living Donor Protection Act of 2021 (LDDPA), S. 377 and H.R. 1255 will make it significantly easier for people to donate a kidney and ultimately move more people off dialysis.

• Transplants for All is our new initiative to ensure that any patient who wants a transplant can get one. We believe that transplantation, which is the gold standard of treatment, should be available to every patient facing kidney failure. Right now, only a fraction of patients with kidney failure will ever have access to transplantation, let alone get one. Every day, 12 people die while on the transplant waitlist. To make the problem even more intolerable, people of color are disproportionately less likely to have access to transplantation creating yet another system plagued by inequality. In FY21, we set three goals for the next five years to get us closer to Transplants for All:
  » Increase living-donor transplantation;
  » Increase deceased-donor transplantation;
  » Increase eligibility and access to transplantation.
WHAT’S NEW:

THE NATIONAL KIDNEY FOUNDATION is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. Most importantly, we use our resources to tackle the critical big-picture issues that individual patients can’t do alone.

- Of the 37 million adults in the U.S. with kidney disease, a disproportionate number are people of color. Seeking to understand and address some of the health disparities facing kidney patients, NKF joined with the American Society of Nephrology (ASN) to form a joint Task Force to examine the role of race in diagnosing kidney diseases. In July 2020, our joint Task Force was formed to examine inclusion of race in the estimation of GFR and its implications for the diagnosis and subsequent management of patients with, or at risk for, kidney diseases. As the largest organizations representing kidney patients, we are committed to ensuring that racial bias does not affect the diagnosis and subsequent treatment of kidney diseases. The Task Force includes a broad range of experts and stakeholders, including patients. In August 2020, we announced the members of the Task Force, and in December 2020, we held a series of public forums seeking input from the kidney community. Read more about the team’s findings and recommendations in the chapter “What’s to Come in FY22.”

- Independently, in December, we advanced the discussion of race in the eGFR equation with the publication of A New Panel Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population in NKF’s American Journal of Kidney Diseases. The study was led by principal investigator Lesley A. Inker, MD, MS, Division of Nephrology, Tufts Medical Center, Boston. The study found that it is possible to accurately assess patients for the stages of kidney disease without using race. The more accurate the diagnosis, the better the treatment options will be considered for each stage, and the better for patients overall.

- To further help address the health disparities facing the kidney community, NKF launched the first-ever Health Equity Advisory Committee to align our efforts in advocacy, research, education, programs, innovation, and awareness to support healthcare equity. We are working to root out any systemic barriers to our goal that all people living with kidney disease, or who are at risk, have full access to resources and quality healthcare.

- We announced a partnership with Renalytix AI (NASDAQ: RNLX) to improve kidney disease diagnosis and assessment in the earliest stages of the disease that will ultimately help guide clinical interventions and treatments for improved outcomes and quality of life. NKF and Renalytix AI will collaborate for the first time in their histories on future studies to assess current care standards in early-stage kidney disease, identify barriers to better care, and assess opportunities for improvement.

- Healthy.io, the creator of smartphone urinalysis, partnered with NKF to offer its home urine albumin-to-creatinine ratio (uACR) test kit free to people with type 2 diabetes who took NKF’s Kidney Risk Quiz. The MinuteForYourKidneys.org quiz is part of NKF’s “Are You the 33%?” awareness campaign.

- We launched a microsite on kidney.org for patients called “What You Should Know” a comprehensive resource of the latest information on COVID-19 and kidney disease. Read more about these efforts in the chapter “Kidney Health Awareness for All.”

FOCUS on patients

45 TRAININGS of THE BIG ASK: THE BIG GIVE in FY21

5 ONLINE FORUMS for kidney patients with 11,534 members
KIDNEY HEALTH
awareness for all

Within days of the COVID-19 pandemic declaration in March 2020, NKF began an all-out effort to support kidney patients, who face risk of serious illness if they contract the virus. By the first day of this fiscal year, April 1, we had created and still maintain the microsite kidney.org/COVID-19 to share with patients everything they need to know about the coronavirus and how it affects kidney patients. Our microsite has received more than a million pageviews and 19.4 million impressions. Thanks to our improved SEO efforts and the quality of our COVID-19 content, we are ranked number 1 for many crucial key word searches in Google regarding vaccination, transplant, kidney disease, and more.

As the pandemic began to close our country, we began a series of free, all-access Facebook Live and Zoom episodes for patients on how to handle their kidney care during the pandemic. We covered urgent topics in both English and Spanish that received great engagement.

- All episodes combined received 159,000 views (live views and post views).
- Our Facebook Live content provided additional value in the form of video vignettes related to specific COVID-19 topics.
- To date, the videos have received a combined 184,000 views on YouTube.

We produced short videos for patients on how to make a DIY mask from a T-shirt; how to properly wash your mask; and shelf-stable recipes.

- The videos received a combined 69,000 views across all social platforms.

We created a video featuring several of our dedicated staff members, ensuring patients that we are “still here for them.”

During the worst of the pandemic, NKF spokespeople proactively gave interviews to media outlets, and we issued a series of press releases to raise the red flag about the urgent needs of kidney patients to keep them safe. The outreach resulted in more than 472 million traditional media impressions and 5.4 million social media impressions.

We also implemented additional awareness efforts during the pandemic that included:

- A weekly blog from our CEO Kevin Longino reassured patients, professionals, and the NKF family during the height of uncertainty.
- Our senior leadership sent weekly email blasts to keep the NKF staff up to date on the ever-changing landscape COVID-19 brought to the world; and
- We changed the NKF logo to an animation reminding everyone to social distance.

In September, we relaunched one of our most important awareness campaigns, the “Are You the 33%?” campaign, to the general public, who may not know anything about kidney disease or why they should. We may have had to pause the campaign in March 2020, but by September we redesigned it and had it ready to coincide with Hispanic Heritage Month. We added a microsite in Spanish. Actor, activist, entrepreneur Wilmer Valderrama served as our spokesperson. He also met with Members of Congress to advocate for kidney patients. Actress Debbie Allen joined the campaign in February to emphasize the link between type 2 diabetes and the risk of kidney disease. Since the campaign was first launched, it has resulted in phenomenal metrics:

- 1.1 billion impressions in traditional media, PSAs, paid and organic social media posts;
- 135,000 people have taken the MinuteForYourKidney.org quiz;
- The quiz conversion rate hit 34%, an industry high; and
- 417,000 page views were clocked at the microsite.

To celebrate Black History Month in February, we launched a special social media tribute to Black and African Americans who have made special contributions to advance kidney health, awareness, and treatment.

WHAT’S NEW:

RIGHT NOW, 37 million Americans are affected by kidney disease. Most won’t have any symptoms unless their kidneys fail. Life-threatening kidney disease can strike anyone, young or old, and has many causes. Early intervention can make a difference. We are working to reach each and every one of those who are at risk of kidney disease before it progresses to life-threatening stages.

- Within days of the COVID-19 pandemic declaration in March 2020, NKF began an all-out effort to support kidney patients, who face risk of serious illness if they contract the virus. By the first day of this fiscal year, April 1, we had created and still maintain the microsite kidney.org/COVID-19 to share with patients everything they need to know about the coronavirus and how it affects kidney patients. Our microsite has received more than a million pageviews and 19.4 million impressions. Thanks to our improved SEO efforts and the quality of our COVID-19 content, we are ranked number 1 for many crucial key word searches in Google regarding vaccination, transplant, kidney disease, and more.
- As the pandemic began to close our country, we began a series of free, all-access Facebook Live and Zoom episodes for patients on how to handle their kidney care during the pandemic. We covered urgent topics in both English and Spanish that received great engagement.
- All episodes combined received 159,000 views (live views and post views).
- Our Facebook Live content provided additional value in the form of video vignettes related to specific COVID-19 topics.
- To date, the videos have received a combined 184,000 views on YouTube.
- We produced short videos for patients on how to make a DIY mask from a T-shirt; how to properly wash your mask; and shelf-stable recipes.
- The videos received a combined 69,000 views across all social platforms.
- We created a video featuring several of our dedicated staff members, ensuring patients that we are “still here for them.”
- During the worst of the pandemic, NKF spokespeople proactively gave interviews to media outlets, and we issued a series of press releases to raise the red flag about the urgent needs of kidney patients to keep them safe. The outreach resulted in more than 472 million traditional media impressions and 5.4 million social media impressions.
- We also implemented additional awareness efforts during the pandemic that included:
  - A weekly blog from our CEO Kevin Longino reassured patients, professionals, and the NKF family during the height of uncertainty.
  - Our senior leadership sent weekly email blasts to keep the NKF staff up to date on the ever-changing landscape COVID-19 brought to the world; and
  - We changed the NKF logo to an animation reminding everyone to social distance.
- In September, we relaunched one of our most important awareness campaigns, the “Are You the 33%?” campaign, to the general public, who may not know anything about kidney disease or why they should. We may have had to pause the campaign in March 2020, but by September we redesigned it and had it ready to coincide with Hispanic Heritage Month. We added a microsite in Spanish. Actor, activist, entrepreneur Wilmer Valderrama served as our spokesperson. He also met with Members of Congress to advocate for kidney patients. Actress Debbie Allen joined the campaign in February to emphasize the link between type 2 diabetes and the risk of kidney disease. Since the campaign was first launched, it has resulted in phenomenal metrics:
  - 1.1 billion impressions in traditional media, PSAs, paid and organic social media posts;
  - 135,000 people have taken the MinuteForYourKidney.org quiz;
  - The quiz conversion rate hit 34%, an industry high; and
  - 417,000 page views were clocked at the microsite.
- To celebrate Black History Month in February, we launched a special social media tribute to Black and African Americans who have made special contributions to advance kidney health, awareness, and treatment.
- Please read about more of our other awareness efforts throughout this annual report.

Actor, activist, entrepreneur, Wilmer Valderrama, a funny guy with a serious message. Play Spanish
NKF by the numbers

7 billion media impressions of NKF content in FY21

4.5 million Twitter impressions of NKF content in FY21

13.1 million Facebook impressions of NKF content in FY21

22.400 Followers
259,000 Followers
36,200 Followers
36,300 Followers

38.9 million page views, kidney.org in FY21

22.3 million users on kidney.org in FY21

TOP 3 PAGES ON KIDNEY.ORG
1. 10 Signs You May Have Kidney Disease
2. GFR Calculator Tool
3. Estimated Glomerular Filtration Rate

34.8 million unique page views, kidney.org in FY21
1. **NKF never hit pause**—As COVID-19 spread, NKF refocused to offer lifesaving help, advice to kidney patients, professionals, and care partners, and advocated for screenings and protective equipment for health professionals.

2. **The place to go for kidney info**—Patients and families depended on kidney.org, featuring a dedicated COVID-19 microsite and a COVID-19/kidney resource bank, for reliable, continually updated information.

3. **On call for patients throughout the crisis**—The NKF Cares Patient Information Help Line (855.NKF.CARES (855.653.2273); nkfcares@kidney.org) responded to all questions COVID-19 sparked in kidney patients.

4. **Sharing our message with millions**—NKF developed national social media campaign to engage patients about the crucial importance of vaccinations, and featured videos and a podcast with patients, clinicians, and influencers.

5. **Taking the country to “kidney school”**—NKF local offices held more than 30 educational webinars on COVID-19 safety, the impact on transplant and dialysis patients, vaccinations, and more.

6. **The right information at the right time**—NKF healthcare experts began and continue to host an ongoing Facebook Live series that speaks directly to kidney patients with the most up-to-date and reliable, targeted health information.

7. **Briefing the government**—NKF local offices held 10 state-level legislative briefings for 90+ lawmakers, informing them about COVID-19’s devastating impact on kidney patients and how to save their lives during this emergency.

8. **Connecting with state leaders**—NKF reached out to governors nationwide about the importance of vaccine access for the kidney community and the challenges kidney patients face.

9. **Bilingual COVID-19 content**—NKF Cares staff translated COVID-19 content into Spanish to better serve the Spanish-speaking kidney community, who were particularly affected by the crisis.

10. **Speaking up and speaking out for kidney patients**—NKF spokespeople were out front immediately on all major media outlets in the U.S. and Canada. Our efforts reached hundreds of millions of people to help them stay safe, protect life-saving medical procedures during lockdown, and advance critical care needed for kidney patients.

**Learn how NKF handled to mask or not to mask?**

---

**AT A GLANCE**

1. **NKF never hit pause**—As COVID-19 spread, NKF refocused to offer lifesaving help, advice to kidney patients, professionals, and care partners, and advocated for screenings and protective equipment for health professionals.

2. **The place to go for kidney info**—Patients and families depended on kidney.org, featuring a dedicated COVID-19 microsite and a COVID-19/kidney resource bank, for reliable, continually updated information.

3. **On call for patients throughout the crisis**—The NKF Cares Patient Information Help Line (855.NKF.CARES (855.653.2273); nkfcares@kidney.org) responded to all questions COVID-19 sparked in kidney patients.

4. **Sharing our message with millions**—NKF developed national social media campaign to engage patients about the crucial importance of vaccinations, and featured videos and a podcast with patients, clinicians, and influencers.

5. **Taking the country to “kidney school”**—NKF local offices held more than 30 educational webinars on COVID-19 safety, the impact on transplant and dialysis patients, vaccinations, and more.

6. **The right information at the right time**—NKF healthcare experts began and continue to host an ongoing Facebook Live series that speaks directly to kidney patients with the most up-to-date and reliable, targeted health information.

7. **Briefing the government**—NKF local offices held 10 state-level legislative briefings for 90+ lawmakers, informing them about COVID-19’s devastating impact on kidney patients and how to save their lives during this emergency.

8. **Connecting with state leaders**—NKF reached out to governors nationwide about the importance of vaccine access for the kidney community and the challenges kidney patients face.

9. **Bilingual COVID-19 content**—NKF Cares staff translated COVID-19 content into Spanish to better serve the Spanish-speaking kidney community, who were particularly affected by the crisis.

10. **Speaking up and speaking out for kidney patients**—NKF spokespeople were out front immediately on all major media outlets in the U.S. and Canada. Our efforts reached hundreds of millions of people to help them stay safe, protect life-saving medical procedures during lockdown, and advance critical care needed for kidney patients.
WHAT’S NEW:

W ITHOUT NKF’S ANNUAL SUPPORT of research and professional education over the last seven decades, many innovations would have never been developed. The worldwide shutdown in fiscal year 2021 due to the pandemic didn’t lessen our commitment to this critical work and only increased our sense of urgency to support professionals in their quest to make patients’ lives better.

• NKF launched the first-ever national registry for patients at all stages of kidney disease called the NKF Patient Network. It is the only kidney disease registry that has both patient-entered data combined with electronic medical records (EMR). Patients with all stages of kidney disease can register and add their important health information. This personal data combined with the patients’ EMR information can then be used in scientific investigation and research. By joining the network, patients will not only help build this important data set, but they will have access to ongoing clinical trials, health tips, individualized patient education for their specific stage of the disease, as well as joining a community of other patients. The NKF Patient Network will be an important tool for both patients and clinicians.

• In August 2020, we announced a partnership with Geisinger Health Systems on the NKF Patient Network. Geisinger clinicians will encourage patients with kidney disease to enroll in the NKF Patient Network and thereby help build this dataset so important for researchers.

• Research fellows were recognized for their excellence in basic and clinical research at the annual National Young Investigators Forum (YIF) in July 2020. Regional winners were invited to participate virtually and compete for national accolades based on original research they presented at the forum. Final awards were determined through an open competition that was judged by independent clinical experts. The 2020 winners in both categories include: Basic Science: 1st place winner Fabian Bock, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, for his project, RAC1 Maintains Renal Epithelial Integrity and Cytoskeletal Organization and is Required for Normal Nephron and Collecting Duct Development; 2nd place: Joseph Leads, MD, University of Virginia Health System, Charlottesville, VA, for his project, Lack of DJ-1 Amplifies Sepsis-Associated Acute Kidney Injury. 3rd place: Anamaria Tatomir, MD, Johns Hopkins University School of Medicine, Baltimore, MD, for her project, A Novel Genetically Defined Mouse Model of Hypertensive Nephropathy. Clinical Research: 1st place: Dinushika Mohottige, MD, MPH, Duke University Medical Center, Durham, NC, for her project, A Tale of Two Neighborhoods: Association of Neighborhood-Level Social and Environmental Contexts with High CKD Prevalence; 2nd place: Simon Hsu, MD, MS, University of Washington, Seattle, WA, for his project, Serum 25-Hydroxyvitamin D Clearance Is Reduced in Chronic Kidney Disease; 3rd place: Matthew Sinclair, MD, Duke University Medical Center, Durham, NC, for his project, Differences in Clinical Phenotype, Bacterial Genotype, and Outcomes in Hemodialysis-Dependent Patients in the Staphylococcus Aureus Bacteremia Group-Prospective Cohort Study. The National Young Investigators Forum was funded through educational grants provided by Amgen and AstraZeneca.

• In December, NKF and the U.S. Food and Drug Administration (FDA) co-sponsored a scientific workshop on “Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: Clinical Trial Considerations.” Lesley Inker, MD MS, and Hiddo Lambers Heerspink co-chaired the Workshop supported by a multi-disciplinary planning committee. There were more than 90 participants representing government and regulatory agencies (FDA and European Medicines Agency), academic researchers, industry, health economists, and payers, and patients.
CHANGING LAWS
and influencing minds

Big victories are possible when the voices of patients come together as one.

WHAT’S NEW:

ACCELERATING CHANGE IN KIDNEY HEALTH takes deliberate effort to influence the minds of others to see the danger of inaction. Whether it be before lawmakers, public health officials or the general public, NKF is committed to sharing the urgent needs of kidney patients, and raising awareness kidney health, and the dangers of kidney disease.

- This fiscal year, we held two Kidney Patient Summits to advocate for kidney patients with U.S. policymakers. Because of the COVID-19 shutdown in March 2020, the 7th Annual Kidney Patient Summit was postponed to September 2020. Our advocates from nearly all 50 states and actor, activist, entrepreneur, producer Wilmer Valderrama met virtually with lawmakers and policy experts to advance kidney disease prevention, early detection, treatment, research, and access to transplants, including living organ donation. Read more about federal legislation in the chapter “Advancing Kidney Transplantation” and state legislation in the chapter “NKF Serving the Local Communities.”

- In March 2021, we hosted our 8th Annual Kidney Patient Summit, and it was one of our most well-represented advocacy summits yet. We brought together 230 kidney health advocates from around the country to meet virtually with Congressional delegations to inspire action for kidney health. Once again, Wilmer Valderrama joined the meetings to amplify our calls for change and draw attention to the “Are You the 33%?” public awareness campaign to reach the 1 in 3 Americans at risk for developing kidney disease.

- In December 2020, we called on the incoming Biden-Harris administration to prioritize kidney health in their first 100 days in office. We urged the new administration to see kidney disease as a public health crisis. Kidney disease sits at the intersection of three forces that shape health care: first, the new coronavirus became a particular risk to kidney patients; then it was discovered that COVID was damaging kidneys of otherwise healthy people, and lastly, the events of 2020 brought into focus the overall and prevailing inequality and healthcare disparities in communities of color, where both kidney disease and COVID pose a disproportionate risk.

- COVID-19 wreaked havoc on our world over fiscal 2021 in many ways, and we stepped up each time a new issue arose. In May 2020, we joined forces with the American Society of Nephrology to urge the U.S. Department of Health and Human Services to pay attention to the needs of kidney patients as the country was shutting down. Specifically, we fought for the adoption of policies and procedures to ensure kidney patients, and clinicians have access to personal protective equipment, have priority access to COVID-19 testing, and have early access to a vaccine.

- We added the weight of our name to a coalition of dozens of patient organizations on guidelines for policymakers to ensure that patients would have continued access to appropriate telehealth services during and after the COVID-19 public health emergency.

- When the vaccine was first rolled out, we urged the federal government to prioritize kidney patients and kidney care professionals in receiving access to COVID-19 vaccines to reduce their increased risk of severe morbidity and mortality. We also asked the federal government to develop an infrastructure to support the dissemination of the COVID-19 vaccine to kidney patients.

- At the first signs of the pandemic, we fought for vulnerable patients and workers in dialysis centers and applauded the Biden Administration when they announced its new partnership with dialysis clinics nationwide to facilitate COVID-19 vaccination of patients with kidney failure.
The pandemic disrupted our lives in many ways, including how it disproportionately affected communities of color, where there were higher death rates and lack of access to healthcare. We called for affordable healthcare for all access to medication, patient choice, access to trans-plantation and home dialysis. 

On the backdrop of the COVID-19 pandemic, our country faced yet another crisis – violence toward people of color. We turned our attention to advocating for the end of systemic racial inequality, especially in health care. At the policy level, we urged the federal government to provide quality, disaggregated data on all tests, hospitalizations, discharges, and deaths from COVID-19 so we may fully understand the scope of the impact on communities of color. We asked that the government ensure priority testing, contact tracing, vaccination, and funding to high-risk communities, low-income neighborhoods, and communities of color. We also advocated for long-term investments in public health infrastructure in traditionally under-served communities and more funding for kidney research and targeted awareness. Read more about our efforts throughout this report.

- In September 2020, NKF partnered with the Centers for Disease Control and Prevention (CDC) to encourage everyone, especially patients with kidney disease, to get a flu shot. COVID-19 made it more important than ever that Americans be vaccinated against influenza. We recognized the need to reduce the number of hospitaliza-tions during COVID-19 and the burden on the overtaxed health care system.

- As you read in the section “Advancing Kidney Transplantation,” we saw the results of our patients’ and staffs’ advocacy efforts when five states, Kentucky, Missouri, New Jersey, Utah, and Washington, passed state legislation that protects living donors against insurance discrimination. We won’t stop until all states have passed this important protection.

---

191 Advocates representing 43 states attend 2021 Kidney Patient Summit in Washington, D.C.

126 Legislators co-sponsor Living Donor Protection Act

138 Legislators co-sponsor Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act, signed into law in December

Our advocates and actor, activist, entrepreneur, producer Wilmer Valderrama met virtually with lawmakers.
**AIDING**

**The professionals**

29,000 clinicians educated by continuing education activities

115 CME/CE activities in FY21

5,125 professional members

**WHAT’S NEW:**

- In February of 2021, we launched the first Pediatric Chronic Kidney Disease Risk Calculator, a tool specifically designed to assess chronic kidney disease (CKD), also known as kidney disease, in children. The tool will help professionals better predict the risk of disease progression than any method before. The calculator development was led by the NIH funded Chronic Kidney Disease in Children (CKID) Study and NKF Board Member Bradley A. Warady, MD, Chief of the Division of Nephrology and Director, Dialysis and Transplantation at Children’s Mercy Kansas City.

- In December, we released our commentary in support of the 2020 recommendations of the International Society for Peritoneal Dialysis (ISPD). Our team of experts studied the new guidelines and supported its call for a more holistic and patient-centered approach to care. Our Kidney Disease Outcomes Quality Initiative (KDOQI) overwhelmingly endorsed the ISPD’s new direction that physicians should avoid a “cookie-cutter” approach to, and assessment of peritoneal dialysis use in their patients.

- In partnership with the IGA Nephropathy Foundation of America, Inc. (IGANF), we submitted the Voice of the Patient Report on IgA Nephropathy to the U.S Food and Drug Administration (FDA). The report was a compilation of the experiences of hundreds of care partners and patients with IgA nephropathy, a disease that can lead to kidney failure. This important work will help shape drug development, policy, and treatment options for years into the future.

- In August of 2020, in collaboration with the Academy of Nutrition and Dietetics, we published the 2020 Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline on Nutrition in Chronic Kidney Disease that will guide health care practitioners who treat people with all stages of kidney disease. Global adoption and implementation of the KDOQI guidelines has dramatically changed all aspects of chronic kidney disease care in the years since the original nutrition guideline was published.

- In July of 2020, we joined the National Committee for Quality Assurance (NCQA) to launch a new Kidney Health Evaluation for Patients with Diabetes measure. The new HEDIS measure will dramatically increase testing in adults with diabetes to improve kidney disease detection and awareness. This measure has already engaged America’s health insurance plans in quality improvement for diabetic kidney disease, including Aetna®, Blue Cross Blue Shield®, UnitedHealth Group® and others.

- NKF gathered a team of experts in nephrology, transplantation, hepatology, and infectious diseases for the KDOQI review of the KDIGO Hepatitis C Guidelines for Clinicians and provided the most up-to-date perspectives on this evolving field. The commentary was released in April 2020 and is a great example of how KDOQI can assist practitioners in deciding how best to implement a global guideline in the U.S. clinical practice environment.

- Soon after the COVID-19 crisis emerged, we launched the NKF Clinical Digest – COVID-19, which provided professionals a compilation of the latest clinical information regarding COVID-19, curated by NKF subject matter experts. We made it easy for the interdisciplinary team to find current and relevant data on the implications of COVID-19 for people living with kidney diseases.

“I am very pleased that the National Kidney Foundation is making the Pediatric Kidney Failure Risk Calculator widely available to healthcare professionals,”

NKF Board Member Bradley A. Warady, MD, Children’s Mercy Kansas City
In June 2020, UnitedHealth Group launched The HERO Program™ (Helping Employees Receive Organs), which provides financial support to help cover expenses incurred as a result of living organ donation, such as lost wages, travel, and lodging for individuals who donate a kidney, a liver, or bone marrow to a company employee or family member. Living donors do not need to be enrolled in a UnitedHealthcare plan or employed by UnitedHealth Group to participate. The HERO Program is the first program by a large employer that covers living organ donation expenses for employees at other organizations.

“Eliminating financial barriers is key to increasing the number of living organ donations,” said Kevin Longino, Chief Executive Officer of NKF and a kidney transplant patient. “The National Kidney Foundation applauds UnitedHealth Group for its leadership role in setting this extraordinary precedent, and its willingness to share the financial and legal models it used to launch the HERO Program™ with any employer interested in extending this life-saving benefit to employees and potential future living organ donors.”

The Corporate Innovator Award was established to recognize industry partners that have advanced the field of nephrology or transplantation by addressing an unmet medical need, through new programming or improving upon an existing practice, therapeutic, or technology.

Companies interested in extending this life-saving benefit to their employees and potential future living organ donors can visit unitedhealthgroup.com/HERO to learn more.

NKF presented the award during the annual NKF Spring Clinical Meetings, which were held in April 2021.

“My brother gave me the gift of a kidney donation and did so despite the financial implications. At UnitedHealth Group, we know it doesn’t always work out that way, that the financial barriers are significant, and that living-donor transplants have better clinical outcomes. We believe if we can continue to remove financial barriers, we will save lives.”

Andrea Deanovic Schmidt, OptumHealth Transplant Resource Services product director and The HERO Program co-creator.

“The National Kidney Foundation applauds UnitedHealth Group for its leadership role in setting this extraordinary precedent, and its willingness to share the financial and legal models it used to launch the HERO Program”

Kevin Longino, NKF Chief Executive Officer and a kidney transplant patient.
Watch how NKF teams across the country stepped up during a pandemic.

As the global pandemic raged on, NKF teams across the country worked tirelessly to reimagine patient programming for a virtual setting, allowing families to seek support and guidance from the safety of home. Our local staff executed more than 100 programs in only the first six months of lockdown.

**Programmatic Impact**

**Increasing living kidney donation**

THE BIG ASK: THE BIG GIVE (BABG), a program designed to help patients find a living donor, further expanded its reach this year with the launch of BABG—First Steps to Transplant, a program designed specifically to support those who haven’t yet been placed on the kidney transplant waitlist.

Our teams also identified the importance of connecting with underserved communities most at risk for both kidney disease and COVID-19. NKF local offices in Colorado and Pennsylvania became the first to host virtual BABG opportunities entirely in Spanish.

**Educating kidney health professionals**

Embracing the virtual space also made it possible to expand our Renal Roundtable lecture series, providing local kidney health professionals with the latest research, information, and opportunities to network with others who share their passion for improving the lives of kidney patients.

More than 70 Renal Roundtables were held virtually by 20 local offices last year and raised $430,000. That is 50 more events hosted than in 2019.

**Advocacy Impact**

**Advancing public policy to protect living donors**

Passionate NKF Advocates and staff influenced the passage of state legislation to protect living donors with The Living Donor Protection Act (LDPA) across 16 states in 2020–2021. This critical legislation will prevent job losses, denial of insurance coverage, and significantly higher life and disability insurance premiums among individuals who selflessly donate a kidney to save the life of a loved one or complete stranger.

But they didn’t stop there, in more than 10 states, including Maryland, Minnesota, Virginia, Ohio and North Carolina, local teams hosted virtual briefings with state legislators to educate them about COVID-19’s effects on kidney patients.

State by state, many of our offices are working to pass state laws to protect living donors and advance kidney health.
**FUNDRAISING IMPACT**

**Uniting our communities**
Though unable to gather in person, Kidney Walks connected families, fundraisers, and advocates in more than 74 communities across the country with the introduction of Kidney Walk LaceUp, a campaign to encourage participants to join in from their neighborhood local park in a fun, virtual setting. This new addition to the decades-long Kidney Walk program successfully activated kidney health warriors across all 50 states for the first time ever and raised an incredible $3.6 million when other nonprofits were closing their doors.

**Reimagining the social experience**
Capitalizing on the success of our virtual Kidney Walk efforts, teams enacted creative strategies to make friends and loved ones feel connected while safely raising funds and awareness in new ways. For the first time, the annual San Francisco-based NKF Authors Luncheon, an event that brings together prominent authors and book lovers, opened its virtual doors to attendees across the country. The national collaboration resulted in nearly $300,000 raised and a larger audience than ever. Meanwhile, NKF Serving Kentucky hosted their first-ever drive-in gala with “A Night Under the Stars,” raising $130,000 for NKF programs in the region. In 20 states this year, local teams completely reimagined or restructured traditional social event fundraisers for virtual settings.

**Driving additional dollars to NKF programs**
Though uncertainty was the name of the game this season, the NKF Konica Minolta Golf Classic program provided golfers and staff with a touch of near normalcy: the opportunity to gather in the safety of the outdoors to fund our fight against kidney disease. An incredible 19 of 27 annual tournaments—from Kentucky to Iowa—were able to continue as planned despite relocation hurdles, format changes, and additional safety precautions. One tournament, hosted by NKF Serving New England, even exceeded their past year’s fundraising by an unbelievable 365%!

**Finding resilience through the generosity of individuals**
Through it all, YOU stuck with us. Despite personal hardship, so many dedicated members of the kidney community extended their hands in unimaginable ways. The generosity of individuals across the country resulted in 36% growth in year-over-year revenue on Giving Tuesday, a worldwide day of giving, with an additional $32,000 of new fundraising dollars on #GivingTuesdayNow in May, an emergency response to the global pandemic.

Even greater still, nearly 400 committed partners pledged their long-term support to sustain our efforts in communities nationwide with a monthly gift.

We are honored and proud of the outpouring of support from every state and, most of all, the resilience of our NKF family. We are whole because of you.

---

**THE LOCAL COMMUNITY**

There is no “us” without “you.” Give, volunteer, or advocate to help win the fight against kidney disease.

Young Juliana Wright, who has only one kidney, promotes kidney health.
THOUSANDS OF PEOPLE like you around the country have given their time, talents, and treasures all year to raise millions to fund important work led by NKF. After COVID-19 hit the world, our mission became more important and critical than ever before, which is why we are so thankful for our many patrons who have continued to support kidney patients.

See how NKF redefined how we walk for kidney health. 🏃‍♂️

**OUR FINANCIAL overview**

View the complete National Kidney Foundation FY21 financials.
**Combined Financials for NKF and Affiliates — FY21**

All figures are in thousands.

**Public Support and Revenue**

- **11%** Other Income $6,388
- **1%** Membership Dues $797
- **26%** Program Service Fees $15,486
- **35%** Contributions $20,721
- **17%** Net Special Events $9,998
- **100% Total Income** $59,627

**Expenses**

- **10%** Management and General $5,037
- **6%** Fundraising $2,995
- **21%** Community Services $10,994
- **14%** Patient Services $7,069
- **7%** Research $3,491
- **19%** Public Health Education $9,705
- **23%** Professional Education $11,755
- **100% Total Expenses** $51,046

**Total Expenses $51,046**

84% Total Program Expenses

16% Total Support Expenses

**Our Financials**

- **$250,000+**
  - Arthur and Gail Passaier
d
- **$100,000+**
  - Ken Longino and Mary McDowell*
- **$50,000–$99,999**
  - Alan Holmes*
  - Kathleen Mohrin*
  - Ron and Joy Paul*
- **$25,000–$49,999**
  - Joseph Carlucci* Panayiopoulos Family*
  - Barbara and Walter Falset* Stig and Patty Ponski*
  - Bill Sarris* Patricia Sticklin*
  - Anthony Tuggel*
- **$10,000–$24,999**
  - Rick Barnett* Carolyn W. and Charles T. Beadon Foundation* Tom Browne*
  - Dedie Covel*
  - William Deiss* Judi and James Fonzi* John and Mary Gerzema*
  - Richard Goldborough Lanskfield Green*
  - Gordon Hauser* Tom Hought* Holly Kramer, MD*
  - Tracy Mickibren* Joe and Kelly Mullins* John and Carol O'Neil* Edward Oleskaj* Joe and Nicki Parsi* Laura Rosa* Gregory W. Scott Charitable Fund*
  - Mark Tostor*
  - Sumeksa Thavarang**, MD* Susan Thorpe*
- **$5,000–$9,999**
  - Michael and Tiffany Watts*
  - Deborah and Michael West* Norma J. West
  - David Anderson Robert and Judy Aptekar
  - Eduard Arabov* Lauren Agran* Meredith Atkinson*
  - George Bologa* Matt and Pinna Barr* Learned Barry
  - Abigail Dadov Deak* John Beuerlein* David Boyer*
  - Ryan Bradley
  - Edwin Brooks*
  - Sue Carey
  - James Carlson
  - Nimma Chaulin
  - Jonathan Cheek*
  - Sandy Coplon
  - Wallace Davis*
  - Marcy Dentor*
  - Jane Dick
  - Tracy Douglas*
  - Kevin Dunn
  - Tamara and Peggy Dunn
  - Joanne and Ellen Flamm
  - Vera Anne Ford
  - Gaetano Giordano
  - Edward L. Goings
  - John and Marcia Goldman Foundation
  - Marie Elaina Gregory
  - The Jack Webster
  - Grigsby Foundation
  - Daniel Hamersich Louis Hawn
  - Stephen Hentz Mack
  -剪刀和Michael McCollom
  - Paul and Carol Meese*
  - Greg Markoulis and Diane Michaels* Theresia Moller
  - Kathy and Tony Naccarato
  - Paul M. Palasky, MD*
  - The Perimeter Family Foundation
  - Richard and Ellen Richman
  - Leticia Roussev*
  - Lee Ruback*
  - Marilyn Schrader
  - David Schultz
  - The Shatter Foundation*
  - Shockey-Reda Charitable Foundation
  - Indeck Singh
  - Kim Stranka
  - Thane Sorensen
  - Michael Stevenson
  - Harry Stokes
  - Swami Swaminathan*
  - Karen Tabbry*
  - Jim and Bill Vale*
  - Tim Valluzzo
  - John Wang
  - Jim White
  - Jon Wills*
- **$1,000–$4,999**
  - Michael Hootman
  - Jeffery Horn*
  - Charles Hurchalla*
  - Lorna Joness*
  - Jill Kahn
  - Tracy Keogh
  - Peggy Kimberlin
  - Bruce and Coco Lefkowitz
  - Kenneth Livingston*
  - Kara Lineebeer
  - Jodie Lockhart*
  - Alan Lovi*
  - Lane Loyko
  - Jim Mazzoli
  - Harvey Meltzer*
  - Melody Marinho
  - Samuel Marco*
  - Bruce McCollom
  - Paul and Carol Meese*
  - Greg Markoulis and Diane Michaels*
  - Theresia Moller
  - Kathy and Tony Naccarato
  - Paul M. Palasky, MD*
  - The Perimeter Family Foundation
  - Richard and Ellen Richman
  - Leticia Roussev*
  - Lee Ruback*
  - Marilyn Schrader
  - David Schultz
  - The Shatter Foundation*
  - Shockey-Reda Charitable Foundation
  - Indeck Singh
  - Kim Stranka
  - Thane Sorensen
  - Michael Stevenson
  - Harry Stokes
  - Swami Swaminathan*
  - Karen Tabbry*
  - Jim and Bill Vale*
  - Tim Valluzzo
  - John Wang
  - Jim White
  - Jon Wills*
- **$500,000+**
  - Michael Wilson
  - Tracey Wilson*
  - Stanley Shalom Zelony Foundation
- **$1,000–$4,999**
  - Tarek Abdel
  - Ali Abou
  - Joe Adams
  - Sarah Addis
  - Manish Agarwal*
  - Christ AHN
  - Abigail Avis*
  - Tony Asilo
  - Mohynnin Albar
  - Sam and Lisa Almun Family Foundation*
  - Jewel Apan
  - Christopher Aldridge
  - Byron Albin
  - Lorrri Aldin
  - Linda Anderson
  - John W. Alexander
  - Mora Patricia Allen
  - Jill AY
  - Melissa Ali
  - Tomi Allender
  - Rebecca Allen
  - Jason Almond*
  - Linda Almond*
  - Ronni Almond*
  - Ben Alt
  - Brain Ambis
  - Osama Arno, MD
  - Denise Andersen*
  - Cynthia Lynne Anderson
  - Dana Monaghan Anderson
  - Herbert R. Anderson
  - Lukas Andersen
  - Jen Anderson
  - Evelyn Andrusa
  - Julie Andrews
  - Mohanand Ansari
  - Raymond Anhalt
  - John Arnold
  - Andrew Arpagian
- **$250,000+**
  - Sharon Arndt
  - Theresa Arndt
  - Dawn Ashby
  - Cassandra Askew*
  - Raisa Asf
  - Brandy Atkins
  - Lara Atwell
  - Patti Austin
  - Ernest Avila
  - Debora Arin Aylor
  - Neal Aylor
  - Peter S. Axilrod
  - Jane Bae*
  - Debra Zachman Bailey
  - Jaime Bailey
  - Mark Bailey
  - Jan Marie Baker
  - Mary Baker
  - Gail Balakula*
  - Janny and Greg Baldwin
  - Chip Bakh
  - Nancy Bakes
  - Vicky Bahr*
  - Loray Bally
  - Daniel Bamir
  - Matt Barme
  - Marcus Bamgbose
  - Laura Richards Bank
  - Santa Barbara and Debra Barbour
  - Elgie Barfield
  - Brian Barnes*
  - Wendy Barnhill
  - Mari Barodey
  - Anne Barr and Fred Matson
  - Kristen Barros
  - Debbie and Michael Barros
  - Christopher G. Bartosm
  - John Bartling
  - John Bartlow
  - Carol Barton*
  - Sandra Allison Barton
  - Chris Batterson
  - Louie Bara*
  - Annabel Beagle

**Our Supporters**

- The National Kidney Foundation with an annual gift of $1,000+.
- These gifts exclusively support our annual fund, which provides important, unrestricted resources that help us advance our mission and values.
OUR FINANCIAL OVERVIEW

OUR FINANCIALS

Annual Report FY21

Joey Freeman
Michael Brower*
Heidi Brostowicz
Donald Bremme
Teresa Brannon*
John and Clara Brady
Jillian Brackett

Fund*

Deborah Bowles
Wendy Bost
Donna and Jon Boscia*
Boscia Family
Lynn Bos
Bryan Bonsall*
Greg Bombassei
Yamini Bonilla
Brian Bosh

Lynn Bos
Bosca Family Foundation
Donna and Jon Boscia*
Wendy Bost
Jeff Boston
Glen M. Boulger
Deborah Bowles
James Bowman
Joel Brandon
Mike Boysen
Robert Cardinal
Robert Carson
David Cooper

Robert Bland
David Brooks
Michael Brehm

Our Annual Report FY21 highlights our financial results for the fiscal year ended June 30, 2021. We are grateful for the continued support of our donors and community partners.

Financial Highlights:

- Revenues for the fiscal year ended June 30, 2021 were $500,000,000.
- Expenses were $450,000,000.
- Net assets increased by $50,000,000 to $300,000,000.

The organization's balance sheet and financial statements are available for review in the Appendix of this report.

Our Financials

In addition to our financial results, this section provides an overview of our financial condition and the key financial metrics that impact our ability to deliver our mission.

Financial Position:

- Total assets at the end of the fiscal year were $300,000,000.
- Total liabilities were $50,000,000.
- Net assets represent our financial strength and our ability to continue supporting our mission.

Financial Ratios:

- Operating margin: 10%
- Net margin: 5%
- Total assets turnover: 2.5x

The organization's financial statements and key performance indicators are available for review in the Appendix of this report.

Financial Support:

The organization relies on contributions from individual donors, corporate partners, foundations, and government grants to fund our programs and initiatives.

Grateful Acknowledgments:

We extend our appreciation to all of our donors and supporters who made significant contributions during the fiscal year ended June 30, 2021.
CORPORATE AND FOUNDATION PARTNERS CONT.

The Marcus & Millichap Company Foundation
Marcus & Millichap, Inc.
Massachusetts General Hospital Transplantation
Mayo Clinic
The McCutchin Foundation*
Mechanical Construction Services, Inc.
Medical Information MEDITECH Medtrition, Inc.
Merck & Co., Inc.
Miami Valley Hospital Foundation
Microsoft Corporation Mid-Atlantic Nephrology Associates, P.A.
Mid-South Transplant Foundation, Inc.
Mon Family Foundation, Inc.*
ModoCare
John Moffitt Charitable Foundation*
Moonstone Nutrition
MUFO Union Bank, N.A.
Natera, Inc.
National Football League Foundation
National Kidney Services, Inc.
Paul and Angela Neilson DAF
Nephrologists, LLC
Nephrology Associates, PC
North Texas BUILT LLC
Norton Healthcare
Novartis AG
Novo Nordisk A/S
O’Connell Electric
Omeros Corporation
One Legacy
Optik Pharmaceuticals
Opulum, Inc.
Others First, Inc.
Onkura America
Pharmaceutical, Inc.
Oxist Medical, Inc.
PA Department of Health, Bureau of Family Health
Penape Corporation, Inc.
Pentec Health
Pharm, Inc.
Quest Diagnostics
Rastru Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc.
Sanford Health
Sanofi Genzyme
SAP America
SAP National Security Services, Inc.
Sarris Candies, Inc.
Satellite Healthcare
SBAD TREAS 301
Seyfarth Shaw LLP
Shoacan Rada Charitable Foundation, Inc.*
Siemens Medical Solutions USA, Inc.
Spectrum Science
Spicology
STEM Health Washington Glennon Children’s Hospital
St. Louis Community Foundation
Surgical Care of Manhattan
Tallgen, Inc.
Teeny Woods—Planet Fitness Growth Partners, LLC
Tel Family Foundation
Thomson Reuters Corporation
Thriftian Action Team Crowd Fund of Infiniti Community Foundation
Tioto’s Handmade Vodka
Transplant Genomics, Inc.
Travere Therapeutics, Inc.
Trixida, Inc.
Tufts University
UC Health
United Way
University of Maryland Medical System
The University of Michigan Health System
University of Pittsburgh Medical Center (UPMC)
UPMC Corporate
Vanderbilt Mortgage and Finance, Inc.
Veloxis Pharmaceuticals, Inc.
Vertex Pharmaceuticals Inc.
Vifor Pharma, Inc.
Vifor, Inc.
Vitae Pharmaceuticals, Inc.
Wells Fargo
WestFire Systems, Inc.
Wilbraham, Lawler & Baba, P.C.
Wilson Dow Group
Winfred Glessop  and Asean Antons
Yale New Haven Hospital
Primary Care

PLATINUM
Aurinia Pharmaceuticals, Inc.
CVS Kidney Care, LLC.
Elixiris
GlaxoSmithKline plc.
Quest Diagnostics
RenaHyte
GOLD
Akredia Therapeutics, Inc.
Amgen Inc.
Ardleyx
AstraZeneca plc.
Mallinckrodt Pharmaceuticals
Medtronic plc.
Merck & Co., Inc.
Novartis AG
Onkura Pharmaceuticals Co., Ltd.
Pfizer, Inc.
Verbx Corp.

SLIVER
Alexion Pharmaceuticals
Arylum Pharmaceuticals
Bayer HealthCare Pharmaceuticals, LLC
Boehringer Ingelheim
Bristol-Myers Squibb-Pfizer Alliance
Esai Co., Ltd.
Janssen Pharmaceuticals, Inc.
Novo Nordisk
Onkura Renal
Rastru Pharmaceuticals, Inc.
Sanofi Aventis
Strive Health

BRONZE
Anji Pharma
DiaMedica Therapeutics, Inc.
Kaiser Life Sciences

OUR FINANCIALS

OUR FINANCIALS

THE ILLUMINATING COMPANY
INMED Medical Insurance Auto Auctions
Intuitive Surgical, Inc.
JIA RE, Inc. Companion Life Insurance Co.
J & J Shared Services
Janssen Pharmaceuticals, Inc.
Jazz at Lincoln Center
JLL
Johns Hopkins Accounts
Payable Shared Service Center
Johnson & Johnson
Kaiser Permanente
Kennedy Realty Corporation
Kenneth L. and Eva S. Smith Foundation*
Kidney Specialists of Minnesota
Konica Minolta Business Solutions, U.S.A., Inc.
Koppers, Inc.
Lance Office
Licensed Practical Nurses Association of the District of Columbia, Inc.
Lisa Strickler and Mark Gallogly Charitable Fund
Logistics Solutions, Inc.
Louis Bertram Foundation*
Lucia Parkeidt Children’s Hospital
Stanford
Lupus Research Alliance
Make A Difference Foundation, Inc.
Mallinckrodt Pharmaceuticals
The Marcus & Millichap Company Foundation
Marcus & Millichap, Inc.
Massachusetts General Hospital Transplantation
Mayo Clinic
The McCutchin Foundation*
Mechanical Construction Services, Inc.
Medical Information MEDITECH Medtrition, Inc.
Merck & Co., Inc.
Miami Valley Hospital Foundation
Microsoft Corporation Mid-Atlantic Nephrology Associates, P.A.
Mid-South Transplant Foundation, Inc.
Mon Family Foundation, Inc.*
ModoCare
John Moffitt Charitable Foundation*
Moonstone Nutrition
MUFO Union Bank, N.A.
Natera, Inc.
National Football League Foundation
National Kidney Services, Inc.
Paul and Angela Neilson DAF
Nephrologists, LLC
Nephrology Associates, PC
North Texas BUILT LLC
Norton Healthcare
Novartis AG
Novo Nordisk A/S
O’Connell Electric
Omeros Corporation
One Legacy
Optik Pharmaceuticals
Opulum, Inc.
Others First, Inc.
Onkura America
Pharmaceutical, Inc.
Oxist Medical, Inc.
PA Department of Health, Bureau of Family Health
Penape Corporation, Inc.
Pentec Health
Pharm, Inc.
Quest Diagnostics
Rastru Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc.
Sanford Health
Sanofi Genzyme
SAP America
SAP National Security Services, Inc.
Sarris Candies, Inc.
Satellite Healthcare
SBAD TREAS 301
Seyfarth Shaw LLP
Shoacan Rada Charitable Foundation, Inc.*
Siemens Medical Solutions USA, Inc.
Spectrum Science
Spicology
STEM Health Washington Glennon Children’s Hospital
St. Louis Community Foundation
Surgical Care of Manhattan
Tallgen, Inc.
Teeny Woods—Planet Fitness Growth Partners, LLC
Tel Family Foundation
Thomson Reuters Corporation
Thriftian Action Team Crowd Fund of Infiniti Community Foundation
Tioto’s Handmade Vodka
Transplant Genomics, Inc.
Travere Therapeutics, Inc.
Trixida, Inc.
Tufts University
UC Health
United Way
University of Maryland Medical System
The University of Michigan Health System
University of Pittsburgh Medical Center (UPMC)
UPMC Corporate
Vanderbilt Mortgage and Finance, Inc.
Veloxis Pharmaceuticals, Inc.
Vertex Pharmaceuticals Inc.
Vifor Pharma, Inc.
Vifor, Inc.
Vitae Pharmaceuticals, Inc.
Wells Fargo
WestFire Systems, Inc.
Wilbraham, Lawler & Baba, P.C.
Wilson Dow Group
Winfred Glessop  and Asean Antons
Yale New Haven Hospital
Primary Care

PLATINUM
Aurinia Pharmaceuticals, Inc.
CVS Kidney Care, LLC.
Elixiris
GlaxoSmithKline plc.
Quest Diagnostics
RenaHyte
GOLD
Akredia Therapeutics, Inc.
Amgen Inc.
Ardleyx
AstraZeneca plc.
Mallinckrodt Pharmaceuticals
Medtronic plc.
Merck & Co., Inc.
Novartis AG
Onkura Pharmaceuticals Co., Ltd.
Pfizer, Inc.
Verbx Corp.

SLIVER
Alexion Pharmaceuticals
Arylum Pharmaceuticals
Bayer HealthCare Pharmaceuticals, LLC
Boehringer Ingelheim
Bristol-Myers Squibb-Pfizer Alliance
Esai Co., Ltd.
Janssen Pharmaceuticals, Inc.
Novo Nordisk
Onkura Renal
Rastru Pharmaceuticals, Inc.
Sanofi Aventis
Strive Health

BRONZE
Anji Pharma
DiaMedica Therapeutics, Inc.
Kaiser Life Sciences
WHAT’S TO COME in FY22

WHAT’S NEW:

As you reach the end of the FY21 annual report, you can see that we have had an unprecedented year. Fiscal year 2022, which had already begun at press time, will be another landmark year at NKF and within the kidney community. Here are just a few highlights of what has begun or is around the corner in our next fiscal year:

• In FY22, we will unveil the critical results of the NKF/ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. The task force gathered to not only reevaluate the long-standing practice of adding a race modifier to kidney function diagnosis, but they are determining to uncover a suitable replacement. We shared the interim report in April 2021 that reviewed alternative methods of testing without a race modifier in the equation. When the final report is issued, we believe the groundbreaking work will help close gaps in kidney healthcare for Black and African American people and provide a more accurate approach to the diagnosis and treatment of kidney diseases.

• Our annual 2021 Spring Clinical Meetings fell at the start of FY22 and was a great success. We held it again virtually and with high participation. Our keynote speaker Aletha Maybank, MD, MPH, who currently serves as the Chief Health Equity Officer and Senior Vice President for the American Medical Association (AMA), called out hate and racism as a public health crisis, one that we all need to address now. “In order to dismantle systemic racism, we must first recognize how it is ingrained in every aspect of society and is constantly operating to drain, exploit, and harm,” Dr. Maybank said. “From there, we can take meaningful collective action and ensure accountability, especially at the institutional level, to advance equity and justice across our healthcare and other social systems.”

• In FY22, we are rolling out our new online children’s educational program about kidneys and how they work. This early education about these critical organs will reach children in grades 5 to 8. Five kid-friendly educational videos, narrated by NKF Kid Ambassador Angelica Hale of America’s Got Talent fame, are available at kidney.org/kids as well as a teacher toolkit, suggestions for youth to demonstrate or teach others what they have learned, and additional activities for children ages 3 and up. By reaching out to children, we have the best chance of teaching people healthy habits that protect kidneys throughout life. They might even influence their parents’ habits, too.

• Through the coming fiscal year, we will build on the success of the “Are You the 33%?” awareness campaign with new partnerships, more targeted marketing, and by drawing connections between kidney disease and other chronic illnesses. We will specifically educate those in underserved communities of color currently suffering in many ways due to healthcare inequality. With the number of people at risk of kidney disease, it is critical that we educate as many Americans as we can about the importance of knowing their kidney health and speaking with their doctors about their kidney health status.